- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00209144
Phase 1 Study of Potential Anti-Inflammatory Effects of Glucose Control During Acute Myocardial Infarction.
Effects of Intense Glycemic Control on Markers of Inflammation and Thrombosis in Patients Treated With Percutaneous Coronary Intervention for Acute Myocardial Infarction.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Two out of three heart attack patients have high blood sugar. Half of these patients have diabetes and the other half have what is called pre-diabetes, meaning that they have higher blood sugar than normal but not high enough to have diabetes. Over 40 million Americans have pre-diabetes.
For more than 70 years, doctors have known that patients with high blood sugar do not survive or recover from heart attacks as well as patients with normal blood sugar. Doctors have not figured out the reason for this difference.
The best treatment available for heart attacks is called angioplasty. Angioplasty means that doctors put a small balloon into a blocked blood vessel, blow up the balloon to open the blockage, and then insert a small wire tube called a stent to hold the blockage open. Blood thinners and other heart medicines are also given to these patients to help blood get through the blocked blood vessel. Angioplasty and these medicines have helped many people survive and recover from heart attacks. But even when doctors use these drugs, balloons and stents, patients who have high blood sugar still do worse than patients with normal blood sugar.
We want to figure out why high blood sugar is bad for patients with heart attacks. Past research tells us there might be two reasons. The first is that high blood sugar increases inflammation which is part of the body's natural response to heart attack. Inflammation is what causes a person's skin to turn hot and red after it is injured. Although inflammation is part of the body's natural healing process, too much inflammation can be harmful. We think that patients with high blood sugar during heart attacks have too much inflammation. The second reason why high blood sugar might be bad for heart attack patients is that high blood sugar makes blood thicker. When a blood vessel is blocked, thick blood makes it harder for the heart to get the blood flow it needs. This is why doctors use aspirin and other blood thinners when they treat patients with heart attacks.
The amount of inflammation and thickness in a person's blood can be measured in a laboratory. In this study, we want to measure the amount of inflammation and thickness in patients' blood to see if there is a difference between patients with normal blood sugar, patients with pre-diabetes, and patients with diabetes. If we can show that there is a difference, this will help us to understand why high blood sugar is bad for patients with heart attacks.
We also want to see if lowering a patient's high blood sugar is helpful during a heart attack. The standard therapy for lowering blood sugar in diabetic patients with heart attacks is to check their blood sugar four times each day while they are in the hospital, and to give them a shot of a medicine called insulin that helps bring the blood sugar level down if it is high. However, research tells us that this way of treating diabetic patients doesn't get their blood sugar low enough. Also, patients with pre-diabetes and patients who have diabetes but don't know it usually don't get any insulin, so their sugar levels are usually allowed to run high while they are in the hospital. In this study, we will treat half of diabetic and pre-diabetic patients the usual way and give the other half insulin through an IV for the first 24 hours that they are in the hospital. If we compare the inflammation and blood thickness between patients treated the usual way and patients treated with more insulin, we can figure out if lowering blood sugar more than usual is helpful to patients with heart attack.
If we can find out why high blood sugar is harmful to patients with heart attacks, and if we can show that treating these patients with more insulin than usual lessens these harmful effects, then we will be able to improve the way that these patients are treated. This could result in better survival and recovery for many heart attack patients.
All patients who volunteer for this study will get the best treatment available for heart attack- angioplasty, blood thinners, and the other heart medications that are usually given to these patients. Patients who have high blood sugar will be divided into two groups. One group will have their blood sugars measured and treated in the usual way. The other group will be treated with insulin run through an IV for 24 hours. After 24 hours, all patients will be treated in the usual way.
About one tablespoon of blood will be drawn from each patient at the time they sign up for the study and then 6, 12, 24, and 48 hours later. This blood will be used to test for inflammation and blood thickness.
The only ways in which patients who volunteer for this study will be treated differently from the standard of care are that they might receive more insulin than usual and they will have more blood drawn than usual. Giving extra insulin to these patients should not cause them harm, and may even help them. Since only about 5 tablespoons of extra blood will be drawn from each patient, this should not cause patients any harm.
Goals of this study
- To see what happens to blood inflammation and thickness in heart attack patients with normal blood sugar and compare this to patients with high blood sugar.
- To find out lowering patients' blood sugar levels more than we currently do will result in less blood inflammation and thickness.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Emory University Hospital
-
Atlanta, Georgia, Stany Zjednoczone, 30329
- Emory Crawford Long Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria: Patients to be treated with percutaneous coronary intervention for myocardial infarction.
Exclusion Criteria: MI > 6 hrs duration Thrombolytic therapy (within last 2 days) Recent inflammatory/infectious illness (last 2 weeks) Pregnancy Renal insufficiency (Cr > 2.0) Type I Diabetes Mellitus Initial BG >110 but <140 Enrollment in another research study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Angioplasty with Insulin
Coming in with acute infarct and received angioplasty with intensive insulin therapy
|
|
Brak interwencji: Angioplasty w/o Insulin
Coming in with acute infarct and received angioplasty
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
Troponin levels
Ramy czasowe: Baseline, 24 hours, 48 hours, and 72 hours (post-procedure)
|
Baseline, 24 hours, 48 hours, and 72 hours (post-procedure)
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
CRP level
Ramy czasowe: Baseline, 24 hours, 48 hours, and 72 hours (post-procedure)
|
Baseline, 24 hours, 48 hours, and 72 hours (post-procedure)
|
B-type natriuretic peptide levels.
Ramy czasowe: Baseline, 24 hours, 48 hours, and 72 hours (post-procedure)
|
Baseline, 24 hours, 48 hours, and 72 hours (post-procedure)
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Douglas C Morris, MD, Emory Heart Center
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 867-2004
- 6-56553
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Ostry zawał mięśnia sercowego
-
Lundquist Institute for Biomedical Innovation at...RekrutacyjnyDługodystansowy COVID lub Post Acute Sequella COVID - PASC (U09.9)Stany Zjednoczone
-
Intermountain Health Care, Inc.Regeneron PharmaceuticalsJeszcze nie rekrutacjaPost-acute COVID-19 (PACS) lub zespół „długiego COVID-19”.Stany Zjednoczone
Badania kliniczne na Intensive insulin therapy
-
University Hospital, Basel, SwitzerlandRekrutacyjnyZanik mięśni u krytycznie chorychSzwajcaria
-
Diasome PharmaceuticalsZakończonyCukrzyca typu 1Stany Zjednoczone
-
Michigan State UniversityZakończonyĆwiczenie | InsulinaStany Zjednoczone
-
I.R.C.C.S. Fondazione Santa LuciaCampus Bio-Medico UniversityZakończonyUderzenie | Niedowład | Paraliż kończyn górnychWłochy
-
Karadeniz Technical UniversityZakończonyHemodializa | Samotność | Szczęście | Dostosowanie | Terapia wspomagana przez zwierzęta | ObjawIndyk
-
ARCIM Institute Academic Research in Complementary...University Hospital TuebingenZakończony
-
Columbia UniversityZakończony
-
University of Alabama, TuscaloosaUniversity of Maryland; University of MemphisZakończony
-
NeuroTronik Inc.NieznanyOstra niewydolność sercaPanama
-
NeuroTronik Inc.NieznanyNiewydolność serca | Ostra niewydolność sercaParagwaj